Reiter-Owona Ingrid, Rehkaemper-Schaefer Claudia, Arriens Sandra, Rosenstock Philip, Pfarr Kenneth, Hoerauf Achim
Institut für Medizinische Mikrobiologie, Immunologie und Parasitologie, Universitätsklinikum, Bonn, Germany.
Klinik und Poliklinik für Dermatologie und Allergologie, Universitätsklinikum Bonn, Sigmund-Freud Str.25, 53105, Bonn, Germany.
Parasitol Res. 2016 Feb;115(2):761-9. doi: 10.1007/s00436-015-4801-8. Epub 2015 Oct 28.
The sensitivity of a K39 ELISA (Leishmania IgG, Virion/Serion) for the detection of antibodies in patients with imported leishmaniasis was compared with an immunofluorescence assay (IFA), which was applied as "golden standard". The retrospective study comprised 93 IFA-positive or borderline sera from 42 patients with visceral (n = 16) or cutaneous (n = 26) leishmaniasis. Patients had acquired infection predominately in the Mediterranean area or the Middle East. The Leishmania species (Leishmania donovani/infantum, Leishmania tropica, Leishmania major) were identified by real-time PCR. The majority (94%) of first samples from patients with visceral leishmaniasis (VL) tested positive by K39 ELISA. Antibody levels ranged from low to very high (33.19-1990.00 U/ml; median 596.66 U/ml) but did not correlate with the respective IFA titers. High K39 ELISA values correlated with acute infection in immunocompetent individuals. K39 antibodies declined in all individuals after clinically successful therapy, but time to seronegativity varied considerably (51 weeks to >6 years). In patients with cutaneous leishmaniasis (CL), the sensitivity of the K39 ELISA was low (23%) compared to IFA (92% positive). Antibody levels ranged from low to medium (10.85-524.77 U/ml; median 19.77 U/ml). The highest antibody concentrations were seen in L. infantum-infected individuals. Summarizing, a high K39 ELISA value indicates active VL. The assay is, like IFA, not a measure for effective therapy but may support post-treatment monitoring. Low level positivity can indicate subclinical, previous or clinically cured VL or even CL. The K39 ELISA can supplement highly sensitive screening tests in the diagnosis and follow-up of imported leishmaniasis.
将用于检测输入性利什曼病患者抗体的K39酶联免疫吸附测定(利什曼原虫IgG,病毒体/血清体)的灵敏度与作为“金标准”的免疫荧光测定(IFA)进行了比较。这项回顾性研究纳入了42例内脏型(n = 16)或皮肤型(n = 26)利什曼病患者的93份IFA阳性或临界血清。患者主要在地中海地区或中东地区获得感染。通过实时聚合酶链反应鉴定利什曼原虫种类(杜氏利什曼原虫/婴儿利什曼原虫、热带利什曼原虫、硕大利什曼原虫)。内脏利什曼病(VL)患者的大多数(94%)首份样本通过K39酶联免疫吸附测定呈阳性。抗体水平从低到非常高(33.19 - 1990.00 U/ml;中位数596.66 U/ml),但与各自的IFA滴度不相关。K39酶联免疫吸附测定高值与免疫功能正常个体的急性感染相关。在临床治疗成功后,所有个体的K39抗体均下降,但血清转阴时间差异很大(51周至>6年)。在皮肤利什曼病(CL)患者中,与IFA(92%阳性)相比,K39酶联免疫吸附测定的灵敏度较低(23%)。抗体水平从低到中等(10.85 - 524.77 U/ml;中位数19.77 U/ml)。在感染婴儿利什曼原虫的个体中观察到最高抗体浓度。总之,K39酶联免疫吸附测定高值表明存在活动性VL。该测定与IFA一样,不是有效治疗的衡量指标,但可能有助于治疗后监测。低水平阳性可能表明亚临床、既往或临床治愈的VL甚至CL。K39酶联免疫吸附测定可在输入性利什曼病的诊断和随访中补充高灵敏度筛查试验。